drugset / Trial / NCT02851004
Special Combination of BBI608 and Pembrolizumab
NaSingle-groupOpen-labelTreatment
Summary
the efficacy and safety of BBI608 in combination with pembrolizumab
Timeline
- Start
- 2016-10
- Primary completion
- 2020-02-03
- Completion
- 2021-08-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Napabucasin | Small molecule | 240 mg | Oral |
| Subject | Napabucasin | Small molecule | 480 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |